Eye Drop

Ocuphire Pharma has enrolled the first patient in its LYNX-2 phase 3 registration study of phentolamine ophthalmic solution 0.75% for treatment of reduced visual acuity under low-light conditions after keratorefractive surgery.

BOSTON — In this Healio Video Perspective from the ASCRS meeting, Richard L. Lindstrom, MD, overviews two dry eye products from Surface Ophthalmics.

Viatris is launching the first commercially available, FDA-approved eyedrop for the reversal of dilation, according to a press release.

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2024, Douglas Katsev, MD, and Julia Katsev Larson, OD, discuss the use of Miebo for dry eye disease.

OcuTerra Therapeutics is evaluating strategic alternatives after the phase 2 DR:EAM trial failed to meet its primary efficacy endpoint, according to a press release.

Exonate has announced successful safety and tolerability data from its phase 1b/2a trial of EXN407, a topical small-molecule therapeutic for retinal vascular diseases, such as diabetic retinopathy and diabetic macular edema.

The FDA approved clobetasol propionate ophthalmic suspension 0.05% for the treatment of inflammation and pain after ocular surgery, according to a press release from Formosa Pharmaceuticals and AimMax Therapeutics.

The FDA has issued a warning to consumers not to purchase or use South Moon, Rebright or FivFivGo eye drops because of possible contamination and risk for eye infection.

You know when you’ve got really good news about something super cool that’s gonna make a lot of your favorite people really happy, and you have to keep it a secret?

WAILEA, Hawaii — In this Healio Video Perspective from Hawaiian Eye/Retina 2024, John A. Hovanesian, MD, FACS, discusses the benefits of treating corneal ulcers with Fortisite, a combination of tobramycin 1.5% and vancomycin 5%.